Squamous Cell Carcinoma — Trials

Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 976
Recruiting: 519
Ph III recruiting: 60
Growth YoY: +44.4%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (402)

clinicaltrialsPublishedShowing 151–200 of 1,119 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07484139	H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)(NEO COMBAT XL)	not yet recruiting	Phase 2	26	UNC Lineberger Comprehensive Cancer CenterOTHER	1	Aug 31, 2026	clinicaltrials
NCT07794813	Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer	recruiting	—	40	Yunnan Cancer HospitalOTHER